Medartis Forecast, price target & analysts
Medartis Target price 2025 - Analyst rating & recommendation
Medartis Classifications & Recommendation:
Medartis Price Target
| Target Price | CHF90.98 |
| Price | CHF83.90 |
| Potential |
8.44%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Medartis 2026 .
The average Medartis target price is CHF90.98.
This is
8.44%
register free of charge
CHF97.02
15.64%
register free of charge
CHF86.86
3.53%
register free of charge
|
|
| A rating was issued by 7 analysts: 5 Analysts recommend Medartis to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medartis stock has an average upside potential 2026 of
8.44%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 224.83 | 266.61 |
| 6.05% | 18.58% | |
| EBITDA Margin | 18.76% | 17.14% |
| 52.45% | 8.64% | |
| Net Margin | 1.57% | 5.97% |
| 436.89% | 280.24% |
5 Analysts have issued a sales forecast Medartis 2025 . The average Medartis sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Medartis EBITDA forecast 2025. The average Medartis EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Medartis Analysts have issued a net profit forecast 2025. The average Medartis net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 0.29 | 1.28 |
| 480.00% | 341.38% | |
| P/E | 65.34 | |
| EV/Sales | 4.21 |
5 Analysts have issued a Medartis forecast for earnings per share. The average Medartis EPS is
This results in the following potential growth metrics and future valuations:
Current Medartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | May 13 2025 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Aug 20 2024 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Aug 19 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jul 16 2025 |
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Aug 20 2024 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Aug 19 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
